Sutro Biopharma, Inc
111 Oyster Point Blvd
South San Francisco
California
94080
United States
Tel: 650.881.6500
Website: http://www.sutrobio.com/
Email: general@sutrobio.com
About Sutro Biopharma, Inc
Sutro Biopharma, Inc., headquartered in South San Francisco, is a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs). Sutro has two wholly owned ADCs in the clinic—STRO-002, a folate receptor alpha (FolRα)-targeting ADC, in clinical studies for ovarian and endometrial cancers; and STRO-001, a CD74-targeting ADC, in clinical studies for B-cell malignancies.
Additionally, Sutro is collaborating with Bristol Myers Squibb (BMS) on CC-99712, a BCMA-targeting ADC in the clinic for patients with multiple myeloma; with Merck KGaA, Darmstadt, Germany, known as EMD Serono in the U.S. and Canada (EMD Serono), on M1231, a MUC1-EGFR bispecific ADC in clinical studies for patients with solid tumors, particularly non-small cell lung cancer (NSCLC) and esophageal squamous cell carcinoma; with Merck, known as MSD outside of the United States and Canada, on MK-1484, a selective IL-2 agonist in clinical studies as a monotherapy and in combination with pembrolizumab for the treatment of solid tumors; and with Astellas Pharma (Astellas) on novel modality, immunostimulatory antibody-drug conjugates (iADCs). Sutro’s platform technology also enabled the spin out of Vaxcyte (Nasdaq: PCVX) and the creation of VAX-24, a 24-valent pneumococcal conjugate vaccine in clinical studies for the prevention of invasive pneumococcal disease. Sutro’s rational design and precise protein engineering has enabled six product candidates in the clinic.
Sutro is dedicated to transforming the lives of cancer patients by creating medicines with improved therapeutic profiles for areas of unmet need. To date, Sutro’s platform has led to ADCs, bispecific antibodies, cytokine-based immuno-oncology therapies, and vaccines directed at precedented targets in clinical indications where the current standard of care is suboptimal.
The platform allows it to accelerate discovery and development of potential first-in-class and best-in-class molecules through rapid and systematic evaluation of protein structure-activity relationships to create optimized homogeneous product candidates. In addition to developing its own oncology pipeline, Sutro is collaborating with select pharmaceutical and biotech companies to discover and develop novel, next-generation therapeutics.
Follow Sutro on Twitter, @Sutrobio, and at www.sutrobio.com to learn more about our passion for changing the future of oncology.
Stock Symbol: STRO
Our Purpose Is Our Patients
175 articles about Sutro Biopharma, Inc
-
Sutro Biopharma Earns Milestone Payment from Cytokine Derivatives Collaboration with Merck
4/15/2021
- Initiation of an IND enabling toxicology study for the first program under the 2018 collaboration on cytokine derivatives earns a $15 million milestone payment from Merck
-
Sutro Biopharma to Present at Two Upcoming Investor Conferences
4/8/2021
Sutro Biopharma, Inc. , today announced that Chief Executive Officer, Bill Newell , will present at two upcoming investor conferences
-
BioSpace Movers & Shakers, March 26
3/26/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Sutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory Board
3/22/2021
Sutro Biopharma, Inc. announced the strengthening of key leadership roles including the promotion of David Pauling, J.D., M.A., to General Counsel, the promotion of Robert Kiss, Ph.D., to Senior Vice President, Process and Analytical Development, and the appointment of Ana Oaknin Benzaquen, M.D., Ph.D., to Sutro's Clinical Advisory Board.
-
Sutro Biopharma Reports Full Year 2020 Financial Results and Provides Business Highlights and 2021 Anticipated Milestones
3/18/2021
- Year-end 2020 cash, cash equivalents and marketable securities of $326.5 million, with projected runway into the second half of 2023 - Four antibody-drug conjugate programs are now in the clinic that were discovered through Sutro's proprietary and integrated cell-free protein synthesis platform
-
Sutro Biopharma to Participate in the Cowen 41st Annual Healthcare Conference
2/23/2021
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that Bill Newell , Chief Executive Officer, will participate in the Ovarian Cancer Panel discussion on March 2, 2021
-
Sutro Biopharma Announces First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian Cancer
1/21/2021
Sutro Biopharma, Inc. today announced the dosing of the first patient in the dose-expansion cohort of Phase 1 study.
-
While Sutro’s technological platform opens multiple therapeutic doors, the company’s singular focus on homogeneous molecules is a key part of its competitive strategy.
-
Sutro Biopharma to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference
1/5/2021
Sutro Biopharma, Inc. announced that Bill Newell, Chief Executive Officer, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on Thursday, Jan. 14, 2021 at 5:20 p.m. ET / 2:20 p.m. PT.
-
Sutro Biopharma Announces Closing of Upsized $144.9 Million Public Offering, including Full Exercise of the Underwriters' Option to Purchase Additional Shares
12/11/2020
Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced the closing of its upsized public offering of 6,900,00
-
Sutro Biopharma Announces Pricing of $126.0 Million Public Offering
12/8/2020
Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced the pricing of an underwritten public offering of 6,000,000
-
Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual Meeting
12/7/2020
- STRO-001 was generally well-tolerated in patients with late-line NHL with no ocular or neuropathy toxicity signals; MTD has not been reached - - 1 CR & 2 PRs observed in heavily pretreated patients with DLBCL; 1 SD in marginal zone lymphoma; 2 SDs in follicular lymphoma - Fred Hutchinson preclinical models with STRO-001 identifies CD74 as a potential target for the treatment of AML
-
Sutro Biopharma Announced Proposed Public Offering of 5 Million Shares of Common Stock
12/7/2020
Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced a proposed underwritten public offering in which it int
-
As the dose of Sutro Biopharma’s ovarian cancer drug, STRO-002, increased in an ongoing Phase I dose-escalation trial, survival rates have also increased.
-
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
12/3/2020
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today provided a clinical update from the company's ongoing dose-escalation Phase 1 study of STRO-002
-
Sutro Biopharma Announces Appointment of Jon M. Wigginton, M.D., to Board of Directors
12/1/2020
- Dr. Wigginton, leader in immuno-oncology and CMO at Cullinan Oncology, to bring additional strategic expertise to Sutro's Board -
-
Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer
11/24/2020
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-gene
-
Sutro Biopharma Announces the Appointment of Diana Landa as Vice President of Regulatory Affairs and Annie Chang as Head of Investor Relations
11/18/2020
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, announced today the appointment of two executives to the Company's leadership team.
-
Sutro Biopharma to Participate in Four Upcoming Investor Conferences
11/11/2020
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development, and manufacturing company, today announced that Chief Executive Officer, Bill Newell , will participate in four upcoming virtual conferences in November and December of 2020. Presentations Details: 2020 Stifel Virtual Health
-
Sutro Biopharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights and Developments
11/5/2020
Sutro Biopharma, Inc., a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, reported its financial results for the quarter ended September 30, 2020 and its recent business highlights and developments.